1:45 PM
 | 
Dec 09, 2016
 |  BioCentury  |  Finance

Networking for cash

How Kymab attracted two Chinese investors to lead $100 million series C round

After raising its first two rounds from philanthropic investors and large Western institutional funds, antibody platform company Kymab Group Ltd. has leveraged its broad network in Asia into the largest U.K. venture financing of the year.

On Nov. 24, Kymab raised $100 million in a series C round led by two new Chinese investors: ORI Healthcare Fund and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399). Hepalink put in $36.5 million.

Also participating were existing investors Wellcome Trust, the Bill & Melinda...

Read the full 404 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >